The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia

    December 2003 in “ The New England Journal of Medicine
    John J. McConnell, Claus G. Roehrborn, Oliver Bautista, Gerald L. Andriole, Christopher L. Dixon, John W. Kusek, Herbert Lepor, Kevin T. McVary, Leroy M. Nyberg, Harry Clarke, E. David Crawford, Ananias C. Diokno, John F. Foley, Harris E. Foster, Stephen D. Jacobs, Steven A. Kaplan, Karl J. Kreder, Michael M. Lieber, M. Scott Lucia, Gary W. Miller, Mani Menon, Douglas F. Milam, Joe W. Ramsdell, Noah S. Schenkman, Kevin M. Slawin, Joseph A. Smith
    Image of study
    TLDR Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.
    The study investigated the long-term effects of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia (BPH). The study involved 3047 men and lasted for 4.5 years. The results showed that doxazosin and finasteride significantly reduced the risk of overall clinical progression, while combination therapy was more effective than either drug alone. Combination therapy and finasteride alone also reduced the long-term risk of acute urinary retention and the need for invasive therapy. The study concluded that long-term combination therapy with doxazosin and finasteride was safe and effective in reducing the risk of overall clinical progression of benign prostatic hyperplasia.
    Discuss this study in the Community →

    Cited in this study

    4 / 4 results


    1 / 1 results